 "oxford, vaccine trials, coronavirus, covid-19")
An Indian-origin professor's Oxford-based company on Tuesday announced that its Indian partner, the Serum Institute of India (SIIPL), has begun trials of a novel virus-like particle (VLP) vaccine targeting Covid-19 which has the potential to offer a groundbreaking new approach to fighting the pandemic.
Prof Sumi Biswas, Chief Executive Officer and Co-Founder of SpyBiotech – an Oxford University spinoff company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, said the first subjects have been dosed in a Phase I/II trial.
SpyBiotech said it has signed an exclusive global licensing agreement with SIIPL for the development
